Hansoh Pharmaceutical Upgraded to MSCI ESG AA Rating, Achieving Global Peer Leadership

ShanghaiNovember 16, 2023PR Newswire -- Recently, MSCI (Morgan Stanley Capital International), an international authoritative index company, announced the latest annual Environmental, Social and Governance (ESG) rating results. Hansoh Pharma's MSCI ESG rating has been upgraded to AA, reaching a leading level among global peers.

MSCI is one of the internationally authoritative ESG index and rating agencies, and its rating results have become a mainstream investment reference in international capital markets. In recent years, Hansoh Pharma has continuously improved its environmental, social, and governance (ESG) standards. Since first receiving an MSCI ESG rating in 2020, the company’s rating has steadily increased. The latest upgrade to AA rating fully demonstrates MSCI’s high recognition of Hansoh Pharma’s ESG governance practices, including enhancing governance structure, ensuring product quality and safety, improving patient health, promoting green and sustainable development, building business ethics and compliance systems, and managing the supply chain.

Hansoh Pharma has always adhered to the deep integration of ESG principles with corporate operations. While continuously delivering breakthrough innovative therapies to patients, the company actively benchmarks against international ESG best practices, assumes social and environmental responsibilities, and promotes ESG excellence.

About Hansoh Pharma

Hansoh Pharma is a leading innovation-driven pharmaceutical company in China, with subsidiaries including Hansoh Pharmaceuticals, Changzhou Hengbang Pharmaceuticals, and Hansoh Biologics. The company focuses on major disease treatment areas such as oncology, anti-infectives, central nervous system, metabolism, and autoimmune diseases, and is committed to improving the quality of human life through continuous innovation. To date, the company has launched seven innovative drugs, with revenue from innovative drugs accounting for 61.8% of total revenue. Hansoh Pharma has consistently ranked among the top 100 global pharmaceutical companies and has been among the top three in China's Best Industrial Pharmaceutical R&D Product Lines for many years. It is a key national high-tech enterprise and a national technology innovation demonstration enterprise. The company was listed on the Hong Kong Stock Exchange in June 2019 (Stock Code: 03692.HK). For more information, please visit:
https://cn.hspharm.com/